Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Phase 3

Recruiting

Conditions: Pneumococcal Immunization

Interventions: Biological: PCV21 vaccine
Biological: Prevnar 20 vaccine
Biological: M-M-R II vaccine
Biological: Rotarix
Biological: RotaTeq
Biological: Vaxelis vaccine
Biological: Varivax
Biological: Priorix
Biological: VAQTA
Biological: Havrix

First Posted Date: 2025-02-13

Last Posted Date: 2025-05-23

Lead Sponsor: Sanofi

Target Recruit Count: 2320

Registration Number: NCT06824194

Locations: 🇭🇳
Investigational Site Number : 3400002, Tegucigalpa, Honduras
🇭🇳
Investigational Site Number : 3400003, Tegucigalpa, Honduras
🇺🇸
Novak Center for Children's Health- Site Number : 8400073, Louisville, Kentucky, United States

and more 45 locations

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Phase 2

Recruiting

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: SAR442970
Drug: Placebo

First Posted Date: 2025-02-06

Last Posted Date: 2025-05-20

Lead Sponsor: Sanofi

Target Recruit Count: 84

Registration Number: NCT06812988

Locations: 🇦🇷
Investigational Site Number : 0320001, Buenos Aires, Argentina
🇦🇺
Investigational Site Number : 0360001, Parkville, Victoria, Australia
🇮🇱
Investigational Site Number : 3760001, Jerusalem, Israel

and more 9 locations

Actual Use Trial of Tadalafil 5 mg

Phase 3

Recruiting

Conditions: Erectile Dysfunction

First Posted Date: 2025-02-03

Last Posted Date: 2025-02-24

Lead Sponsor: Sanofi

Target Recruit Count: 2250

Registration Number: NCT06805513

Locations: 🇺🇸
Pegus, Salt Lake City, Utah, United States

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Phase 2

Recruiting

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Teplizumab

First Posted Date: 2025-01-24

Last Posted Date: 2025-05-23

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT06791291

Locations: 🇯🇵
Investigational Site Number : 3920007, Yahaba, Iwate, Japan
🇯🇵
Investigational Site Number : 3920004, Osaka-shi, Osaka, Japan

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Phase 2

Recruiting

Conditions: Dermatitis Atopic

Interventions: Drug: Placebo
Drug: Lunsekimig

First Posted Date: 2025-01-23

Last Posted Date: 2025-04-22

Lead Sponsor: Sanofi

Target Recruit Count: 144

Registration Number: NCT06790121

Locations: 🇺🇸
T. Joseph Raoof MD Inc-Site Number: 8400004, Encino, California, United States
🇺🇸
Clinical Trials Research Institute-Site Number: 8400003, Thousand Oaks, California, United States
🇯🇵
Investigational Site Number: 3920005, Asahikawa-shi, Japan

and more 13 locations

A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus

Phase 4

Recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: iGlarLixi (insulin glargine/lixisenatide)

First Posted Date: 2024-12-04

Last Posted Date: 2025-05-21

Lead Sponsor: Sanofi

Target Recruit Count: 105

Registration Number: NCT06716424

Locations: 🇮🇳
Investigational Site Number : 3560003, Kanpur, India
🇮🇳
Investigational Site Number : 3560007, Delhi, India
🇮🇳
Investigational Site Number : 3560005, Hyderabad, India

and more 3 locations